Semnur Pharmaceuticals

What Semnur Pharmaceuticals does

Semnur Pharmaceuticals is a clinical-stage specialty biopharmaceutical company developing non-opioid therapies for pain management, with a single lead asset — SP-102 (SEMDEXA), a preservative-free, surfactant-free, particulate-free viscous gel formulation of dexamethasone sodium phosphate (10 mg at 5 mg/mL, 2 mL deliverable volume) intended for epidural injection to treat lumbosacral radicular pain (sciatica). The formulation uses sodium hyaluronate as a biocompatible, biodegradable excipient that extends residence time at the injection site, packaged in a pre-filled glass syringe for physician-administered delivery. SP-102 has completed a pivotal Phase 3 trial (C.L.E.A.R., 400 patients across 40 U.S. sites) meeting primary and key secondary endpoints, holds FDA Fast Track Designation, and a confirmatory Phase 3 (C.L.E.A.R.-2) is planned for mid-2026 to support an NDA filing. Semnur is a wholly-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX), itself majority-owned by Sorrento Therapeutics (Nasdaq: SRNE), and is preparing to become a standalone Nasdaq-listed entity via a proposed SPAC business combination with Denali Capital Acquisition Corp. (Nasdaq: DECA) at a pre-transaction equity value of up to $2.0 billion.

The company's business model is a traditional specialty pharmaceutical commercial model, not yet generating revenue. Upon FDA approval, SP-102 would be distributed through specialty pharmacy channels to pain management practitioners, interventional pain physicians, and healthcare systems, with peak sales projected at up to $3.6 billion annually 5 years post-launch per a Syneos Health market study. Semnur's target market — patients with moderate-to-severe chronic radicular pain/sciatica — is large (12+ million U.S. ESI procedures annually, 30+ million affected Americans) and currently served only by off-label compounded steroids associated with safety risks including the 2012 fungal meningitis outbreak, positioning SP-102 as a potential first FDA-approved non-opioid epidural corticosteroid. Capital sources to date include a 2013 Series A of approximately $6 million from Canaan Partners, Frazier Healthcare Partners, and Vivo Capital; a planned up to $40 million from the Denali Capital SPAC combination; and two Bitcoin-denominated securities purchase agreements (totaling roughly $100 million) that were terminated without share issuance in April 2026, leaving capital structure execution as a material risk factor.

Name

Semnur Pharmaceuticals

Legal name

Semnur Pharmaceuticals, Inc.

Website

https://semnurpharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Semnur Pharmaceuticals is a clinical-stage biopharmaceutical company developing SP-102 (SEMDEXA), a non-opioid, preservative-free dexamethasone viscous gel for epidural injection to treat lumbosacral radicular pain (sciatica), targeting pain management physicians and healthcare systems in the United States.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals — Non-Opioid Pain Management

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Non-opioid pain management
• Epidural steroid injection
• Corticosteroid gel formulation
• Sciatica treatment therapy
• Specialty pharmaceutical development

Headquarters

HQ city

Los Altos

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SP-102 (SEMDEXA) Commercialization: Once FDA approved, SP-102 will be commercialized as a prescription pharmaceutical product for the treatment of lumbosacral radicular pain/sciatica. The product would be distributed through specialty pharmacy and healthcare channels, generating revenue through product sales. Peak sales potential projected at up to $3.6 billion annually 5 years post-launch.
2. Future Pipeline Products: Semnur plans to expand its product portfolio by developing or acquiring non-opioid assets. Scilex Holding (parent) has additional pipeline products including SP-103 (lidocaine topical system 5.4%) and SP-104 (low-dose naltrexone delayed-release capsules) that may contribute to future revenue.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Semnur Pharmaceuticals is developing SP-102 (SEMDEXA™), the first non-opioid novel injectable corticosteroid gel formulation for epidural administration to treat moderate to severe lumbosacral radicular pain (sciatica). The product is a preservative-free, surfactant-free, particulate-free viscous gel of dexamethasone sodium phosphate using sodium hyaluronate as a biocompatible excipient, delivered via a pre-filled glass syringe. The company is currently in clinical-late stage with completed Phase 3 trials and a planned confirmatory Phase 3 C.L.E.A.R.-2 study for FDA NDA submission.

Product overview

Semnur Pharmaceuticals is a late-stage clinical biopharmaceutical company developing a single lead product candidate, SP-102 (SEMDEXA™), a non-opioid injectable corticosteroid gel formulation for epidural administration. The company is a wholly-owned subsidiary of Scilex Holding Company and focuses exclusively on developing and commercializing this novel non-opioid pain therapy for the treatment of lumbosacral radicular pain (sciatica). The product is administered via epidural injection using a pre-filled glass syringe and completed Phase 3 clinical trials with positive results, currently planning a confirmatory Phase 3 trial (C.L.E.A.R.-2) for NDA submission to the FDA.

Differentiator

Problem solved

Functional benefit

Brands

• SEMDEXA: Brand name for SP-102 (dexamethasone sodium phosphate viscous gel), a non-opioid injectable corticosteroid gel formulation for treatment of lumbosacral radicular pain/sciatica

Products and services

• SP-102 (SEMDEXA™) SP-102 (SEMDEXA™) is Semnur's lead and only product candidate — a non-opioid, preservative-free, surfactant-free, particulate-free viscous gel formulation of dexamethasone sodium phosphate (10 mg at 5 mg/mL concentration, 2 mL deliverable volume) packaged in a pre-filled glass syringe for epidural injection to treat moderate to severe chronic lumbosacral radicular pain (sciatica). It is the first non-opioid novel injectable corticosteroid gel formulation in development for this indication, has received FDA Fast Track Designation, and has completed Phase 3 trials with a confirmatory Phase 3 C.L.E.A.R.-2 study planned.

Quantifiable outcome

• Phase 3 C.L.E.A.R. trial: LS mean treatment difference of -0.52 units in pain score (P=0.002) vs placebo over 4 weeks
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Scilex Holding CompanycoreStrategic or Co-development PartnerScilex Holding Company is the parent and majority owner of Semnur Pharmaceuticals. The companies share management, technology, and operational resources. Henry Ji serves as Executive Chairman of both companies.
• SanofiminorStrategic or Co-development PartnerSanofi is listed as a business partner on Semnur's website, though specific partnership details are not publicly disclosed.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Tonix Pharmaceuticals: Clinical-stage biopharma developing non-opioid pain candidates including TNX-102 SL for fibromyalgia and other CNS pain indications; comparable pipeline approach targeting non-opioid alternatives.
• Vertex Pharmaceuticals: Large biopharma with an emerging non-opioid acute pain pipeline (e.g., VX-548, NaV1.8 inhibitor); comparable investment thesis of capturing share from opioid-based pain treatment, though at much larger scale.

Broad incumbents

• Teva Pharmaceutical Industries: Large specialty and generics pharmaceutical company with pain management offerings including Ajovy and a portfolio of injectable pain therapies; broad incumbent with overlapping distribution relationships with hospitals and pain clinics.
• Pfizer: Global pharmaceutical major with broad pain management portfolio including Celebrex and Lyrica; broad incumbent that competes for prescriber mindshare and payer access in the non-opioid pain category.
• Eli Lilly: Global pharmaceutical major with established pain and neurology franchises (e.g., Cymbalta, Emgality) and active investment in non-opioid pain research; represents incumbent competition for prescriber adoption and payer coverage.

Direct peers

• Heron Therapeutics: Specialty pharma developing and commercializing post-surgical and chronic pain products including Zynrelef and Sustol; comparable specialty sales force targeting hospitals, pain clinics, and interventional specialists.
• AcelRx Pharmaceuticals: Specialty pharmaceutical company developing and commercializing non-opioid pain therapies, including DSUVIA (sufentanil sublingual) and Zalviso; comparable focus on hospital-administered and specialty pain products.
• Pacira BioSciences: Specialty pharmaceutical company focused on non-opioid pain management with EXPAREL (bupivacaine liposome injectable) and iovera; closely comparable business model targeting interventional pain physicians with hospital/clinic-administered injectables.
• Collegium Pharmaceutical: Specialty pharmaceutical company focused on responsible pain management with Xtampza ER and other abuse-deterrent and non-opioid pain therapies; comparable commercial model targeting pain management practitioners.
• Scilex Holding Company: Semnur's parent company and direct corporate peer; Scilex is also developing and commercializing non-opioid pain therapies including ZTlido, sharing management, technology, and operational resources with Semnur, and serves as the consolidating entity for the SP-102 franchise.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/semnurpharma
• LinkedInlinkedin.com/company/semnur-pharmaceuticals-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Semnur Pharmaceuticals